ES2076320T3 - Adyuvante angiografico. - Google Patents

Adyuvante angiografico.

Info

Publication number
ES2076320T3
ES2076320T3 ES90307268T ES90307268T ES2076320T3 ES 2076320 T3 ES2076320 T3 ES 2076320T3 ES 90307268 T ES90307268 T ES 90307268T ES 90307268 T ES90307268 T ES 90307268T ES 2076320 T3 ES2076320 T3 ES 2076320T3
Authority
ES
Spain
Prior art keywords
angiographic
adjuvant
angiographic adjuvant
prostaglandins
clarity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES90307268T
Other languages
English (en)
Inventor
Yasuyuki Gotou
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Taisho Pharmaceutical Co Ltd
Tanabe Pharma Corp
GC Biopharma Corp
Original Assignee
Green Cross Corp
Taisho Pharmaceutical Co Ltd
Green Cross Corp Korea
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Green Cross Corp, Taisho Pharmaceutical Co Ltd, Green Cross Corp Korea filed Critical Green Cross Corp
Application granted granted Critical
Publication of ES2076320T3 publication Critical patent/ES2076320T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/04—X-ray contrast preparations
    • A61K49/0409—Physical forms of mixtures of two different X-ray contrast-enhancing agents, containing at least one X-ray contrast-enhancing agent which is not a halogenated organic compound
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Nanotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

UN ADYUVANTE ANGIOGRAFICO COMPRENDE UNA EMULSION GRASA QUE CONTIENE UN COMPUESTO QUE TIENE PROSTAGLANDINAS E1 ACTIVAS. EN UN METODO ANGIOGRAFICO, EL ADYUVANTE MEJORA LA CLARIDAD DE LOS GRAFICOS RESULTANTES
ES90307268T 1989-07-05 1990-07-03 Adyuvante angiografico. Expired - Lifetime ES2076320T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP1173709A JPH0669966B2 (ja) 1989-07-05 1989-07-05 血管造影補助剤

Publications (1)

Publication Number Publication Date
ES2076320T3 true ES2076320T3 (es) 1995-11-01

Family

ID=15965683

Family Applications (1)

Application Number Title Priority Date Filing Date
ES90307268T Expired - Lifetime ES2076320T3 (es) 1989-07-05 1990-07-03 Adyuvante angiografico.

Country Status (8)

Country Link
US (1) US5445812A (es)
EP (1) EP0407148B1 (es)
JP (1) JPH0669966B2 (es)
KR (1) KR0160127B1 (es)
CA (1) CA2020368C (es)
DE (1) DE69021289T2 (es)
DK (1) DK0407148T3 (es)
ES (1) ES2076320T3 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4135193C1 (es) * 1991-10-22 1993-03-11 Schering Ag Berlin Und Bergkamen, 1000 Berlin, De
US5807895A (en) * 1994-11-29 1998-09-15 Schwarz Pharma, Inc. Use of prostaglandin E1, E2 or analogs to prevent renal failure induced by medical tests that utilize contrast media agents
WO1996016661A2 (en) * 1994-11-29 1996-06-06 Schwarz Pharma, Inc. Use of prostaglandin e1, e2 or analogs to prevent renal failure induced by medical tests that utilize contrast media agents
DE4446694A1 (de) * 1994-12-09 1996-06-13 Schering Ag Verwendung von Zusätzen zu Kontrastmitteln zur Verbesserung der Bildgebung
US5631287A (en) * 1994-12-22 1997-05-20 Alcon Laboratories, Inc. Storage-stable prostaglandin compositions
US6011062A (en) * 1994-12-22 2000-01-04 Alcon Laboratories, Inc. Storage-stable prostaglandin compositions
US6281175B1 (en) 1997-09-23 2001-08-28 Scimed Life Systems, Inc. Medical emulsion for lubrication and delivery of drugs
US6054421A (en) * 1997-09-23 2000-04-25 Scimed Life Systems, Inc. Medical emulsion lubricant
DE19838788A1 (de) * 1998-08-26 2000-03-09 Siemens Ag Geregelter optischer Verstärker
US6246897B1 (en) 1998-12-11 2001-06-12 General Electric Company Method and system for acquistion of preferential arterial and venous images for MR angiography
US6192264B1 (en) 1998-12-28 2001-02-20 General Electric Company Method and system for MRI venography including arterial and venous discrimination
US20080132797A1 (en) * 2002-12-10 2008-06-05 Knut Brabrand Monitoring infusion of a substance
AT518009A1 (de) * 2015-07-27 2017-06-15 Gebro Holding Gmbh Konzentrat enthaltend Alprostadil

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS58222014A (ja) * 1982-06-18 1983-12-23 Taisho Pharmaceut Co Ltd プロスタグランジンｅ↓１脂肪乳剤
JPS59206349A (ja) * 1983-05-10 1984-11-22 Green Cross Corp:The プロスタグランジンｅ↓１誘導体
JPS59216820A (ja) * 1983-05-20 1984-12-06 Taisho Pharmaceut Co Ltd プロスタグランジン脂肪乳剤
JPH0818989B2 (ja) * 1984-01-12 1996-02-28 株式会社ミドリ十字 脂肪乳剤中のプロスタグランジンの安定化方法
DE3421468A1 (de) * 1984-06-08 1985-12-19 Dr. Rentschler Arzneimittel Gmbh & Co, 7958 Laupheim Lipidnanopellets als traegersystem fuer arzneimittel zur peroralen anwendung
JPS61289034A (ja) * 1985-06-17 1986-12-19 Teijin Ltd イソカルバサイクリン類脂肪乳剤
US4820732A (en) * 1985-10-04 1989-04-11 The Upjohn Company Method and compositions for reducing dysfunction in angioplasty procedures
US4955878A (en) * 1986-04-04 1990-09-11 Biotechnology, Inc. Kit for preventing or treating arterial dysfunction resulting from angioplasty procedures
US5120527A (en) * 1989-10-19 1992-06-09 King Chuen Peter Li Paramagnetic oil emulsions as mri contrast agents
US5064636A (en) * 1989-10-19 1991-11-12 Li King C P Paramagnetic oil emulsions as enteric MRI contrast agents

Also Published As

Publication number Publication date
JPH0669966B2 (ja) 1994-09-07
EP0407148B1 (en) 1995-08-02
EP0407148A3 (en) 1992-01-08
CA2020368A1 (en) 1991-01-06
JPH0466540A (ja) 1992-03-02
DK0407148T3 (da) 1995-09-18
KR0160127B1 (ko) 1998-12-01
CA2020368C (en) 2001-09-11
EP0407148A2 (en) 1991-01-09
DE69021289T2 (de) 1996-03-21
KR910002470A (ko) 1991-02-25
DE69021289D1 (de) 1995-09-07
US5445812A (en) 1995-08-29

Similar Documents

Publication Publication Date Title
AR002932A1 (es) Solucion acuosa de interferon
DE3861956D1 (de) Axialkolbenpumpe.
FI873241L (fi) Grafisk arbetstation.
MX9101734A (es) Dispositivo para implantarse en un huesped,que forma estructuras y vasculares en la interfase entre al menos una porcion de dicho dispositivo y el huesped y metodo para implantar dicho dispositivo
ES2052495T3 (es) Terapia de fluidos con aniones l-lactato y/o piruvato.
DE3774322D1 (de) Gasdynamische pumpe.
FI811828A7 (fi) Magneettisesti paikannettavia, biohajaantuvia lipidi- mikropallosia.
MX153211A (es) Mejoras en metodo para fabricar un dispositivo semiconductor con una region de base que tiene una porcion profunda
ES2046852T3 (es) Un procedimiento para preparar un champu.
ES2059053T3 (es) Procedimiento de control de los mejillones cebra empleando un haluro de didecildimetilamonio.
ES2057476T3 (es) Medios para el diagnostico de neuropatias desmielinizantes, en particular de la esclerosis en placas.
NO770492L (no) Aksial stempelpumpe.
CA2020368A1 (en) Angiographic adjuvant
CO4230148A1 (es) Metodo para referenciar datos sismicos mediante modelado a- vanzado
ES2038064B1 (es) Instalacion portatil de vacunacion aviar.
ES2038444T3 (es) Metodo de piscicultura.
JPS5269909A (en) Water-in-oil emulsion fuel
FI885854L (fi) Kolv foer tryckdriven kolvmaskin.
AR247328A1 (es) Procedimiento para reducir e inhibir el contenido de etilentiourea (etu) en los alquilenbisditiocarbomatos
DE58904447D1 (de) Lichtverteilung-darstellungsverfahren.
EA199700449A1 (ru) Способ предотвращения остеопороза
IT8124047A0 (it) Agente antiipertensione.
ES2089091T3 (es) Complejos que contienen acidos s(+)-fenilalcanoicos y acidos alfa-hidroalcanoicos.
ES2058601T3 (es) Formulaciones que contienen heparina.
IT8002918A0 (it) Procedimento per la stabilizzazione di vitamine.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 407148

Country of ref document: ES